Kristie M. Coleman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kristie M. Coleman has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
- Stavros E. Mountantonakis
Northwell Health, New Hyde Park, New York, USA; Lenox Hill Hospital, New York, New York, USA
10 shared publications Nikhil Sharma
Northwell Cardiovascular Institute, 2000 Marcus Ave, New Hyde Park, NY
8 shared publicationsStavros E. Mountantonakis
Northwell Cardiovascular Institute, 2000 Marcus Ave, New Hyde Park, NY
8 shared publicationsHaisam Ismail
Northwell Health, New Hyde Park, New York; Northwell Cardiovascular Institute, New York, New York
7 shared publicationsMoussa Saleh
Northwell Health, New Hyde Park, New York; Northwell Cardiovascular Institute, New York, New York
6 shared publicationsDimitrios Varrias
Northwell Cardiovascular Institute Center for Arrhythmias New Hyde Park New York USA
5 shared publications
Latest Publications
- 4 November 2026
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
Sex-based differences in the atrial fibrillation care pathway and outcomes: an ITHACA-database analysis
Aims: To characterize sex-specific differences in clinical presentation, evaluate progression through the atrial fibrillation (AF) care pathway from diagnosis to catheter ablation (CA) and assess long-term outcomes. Methods and results: This was a retrospective cohort study of patients with incident AF at Northwell Health between 2015 and 2024 from the ITHACA-database. Sex-specific differences in clinical presentation were examined. The AF care pathway was operationalized as a stepwise cascade, modelling conditional drop-off to identify care gaps. Sex-specific CA risk ratios were assessed via Poisson regression. Incident AF was identified among 165 563/655 459 patients (71.4 ± 11.6 years, 32% non-white, 45% female) with a recorded diagnosis of AF. Women were older (73.3 ± 10.6 vs. 69.8 ± 12.1 years, P < 0.001), had higher rates of dementia (9.1% vs. 5.2%), stroke (8.6% vs. 7.4%) and congestive heart failure (21.5% vs. 20.8%) at diagnosis. Transfer-of-care gaps [median 3.6 years follow-up, 96% retention] were identified at every level: 31.5% of women vs. 35.3% of men were evaluated by cardiology, 16.2% vs. 21.6% by electrophysiology, and 3.5% vs. 5.7% underwent CA (all P < 0.001). Women were 16% less likely to receive CA (RR 0.84 95% CI 0.77–0.91). In cause-specific Cox models, female sex was associated with incident stroke (aHR 1.24, 95% CI 1.18–1.30) and dementia (aHR 1.30, 95% CI 1.24–1.35), but modestly lower mortality after adjustment (aHR 0.96, 95% CI 0.94–0.99). Conclusion: In this real-world analysis, significant sex-specific differences in clinical phenotype at presentation, progression through the AF care pathway and clinical outcomes were observed.
- 4 November 2026
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
Sex-based differences in the atrial fibrillation care pathway and outcomes: an ITHACA-database analysis
Aims: To characterize sex-specific differences in clinical presentation, evaluate progression through the atrial fibrillation (AF) care pathway from diagnosis to catheter ablation (CA) and assess long-term outcomes. Methods and results: This was a retrospective cohort study of patients with incident AF at Northwell Health between 2015 and 2024 from the ITHACA-database. Sex-specific differences in clinical presentation were examined. The AF care pathway was operationalized as a stepwise cascade, modelling conditional drop-off to identify care gaps. Sex-specific CA risk ratios were assessed via Poisson regression. Incident AF was identified among 165 563/655 459 patients (71.4 ± 11.6 years, 32% non-white, 45% female) with a recorded diagnosis of AF. Women were older (73.3 ± 10.6 vs. 69.8 ± 12.1 years, P < 0.001), had higher rates of dementia (9.1% vs. 5.2%), stroke (8.6% vs. 7.4%) and congestive heart failure (21.5% vs. 20.8%) at diagnosis. Transfer-of-care gaps [median 3.6 years follow-up, 96% retention] were identified at every level: 31.5% of women vs. 35.3% of men were evaluated by cardiology, 16.2% vs. 21.6% by electrophysiology, and 3.5% vs. 5.7% underwent CA (all P < 0.001). Women were 16% less likely to receive CA (RR 0.84 95% CI 0.77–0.91). In cause-specific Cox models, female sex was associated with incident stroke (aHR 1.24, 95% CI 1.18–1.30) and dementia (aHR 1.30, 95% CI 1.24–1.35), but modestly lower mortality after adjustment (aHR 0.96, 95% CI 0.94–0.99). Conclusion: In this real-world analysis, significant sex-specific differences in clinical phenotype at presentation, progression through the AF care pathway and clinical outcomes were observed.
- Open Access
- 8 October 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (10) , 505
Hybrid Ablation for Patients with Persistent and Long-Standing Persistent Atrial Fibrillation
Atrial fibrillation (AF) is the most commonly encountered arrhythmia, with a rapidly growing prevalence and significant cost to the global healthcare system. Left untreated, AF progresses over time from paroxysmal AF to persistent AF (perAF) and long-standing persistent AF (LS-perAF). AF is associated with significant mortality and morbidity by increasing the risk of developing cardiomyopathy, heart failure, dementia, stroke and systemic embolization. Endocardial catheter ablation (CA) targeting pulmonary vein isolation (PVI) alone is the most commonly employed treatment strategy for patients undergoing invasive treatment for all forms of AF. Despite technological improvements such as pulsed field ablation (PFA), procedural success rates in preventing AF recurrences in patients with perAF and LS-perAF remain suboptimal. A lack of lesion transmurality gives rise to epicardial–endocardial dissociation, which may contribute to AF recurrences. Hybrid ablation (HA) combines epicardial surgical ablation with endocardial CA. HA leads to greater freedom from AF in advanced AF compared to CA, and while existing data support the safety of HA, HA inherently is more invasive, requires a multidisciplinary approach, and has a 5–7.8% risk of major adverse events. HA is reasonable in patients with symptomatic, drug-refractory perAF or LS-perAF. Future directions include evaluating the role of novel operative technologies in HA.
- 8 October 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (10) , 505
Open AccessHybrid Ablation for Patients with Persistent and Long-Standing Persistent Atrial Fibrillation
Atrial fibrillation (AF) is the most commonly encountered arrhythmia, with a rapidly growing prevalence and significant cost to the global healthcare system. Left untreated, AF progresses over time from paroxysmal AF to persistent AF (perAF) and long-standing persistent AF (LS-perAF). AF is associated with significant mortality and morbidity by increasing the risk of developing cardiomyopathy, heart failure, dementia, stroke and systemic embolization. Endocardial catheter ablation (CA) targeting pulmonary vein isolation (PVI) alone is the most commonly employed treatment strategy for patients undergoing invasive treatment for all forms of AF. Despite technological improvements such as pulsed field ablation (PFA), procedural success rates in preventing AF recurrences in patients with perAF and LS-perAF remain suboptimal. A lack of lesion transmurality gives rise to epicardial–endocardial dissociation, which may contribute to AF recurrences. Hybrid ablation (HA) combines epicardial surgical ablation with endocardial CA. HA leads to greater freedom from AF in advanced AF compared to CA, and while existing data support the safety of HA, HA inherently is more invasive, requires a multidisciplinary approach, and has a 5–7.8% risk of major adverse events. HA is reasonable in patients with symptomatic, drug-refractory perAF or LS-perAF. Future directions include evaluating the role of novel operative technologies in HA.
- Open Access
- 23 April 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (23) , 108309
Baroreflex Activation Therapy in HFrEF Patients
- 23 April 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (23) , 108309
Open AccessBaroreflex Activation Therapy in HFrEF Patients
- 15 April 2026
- Published by Elsevier in Heart Rhythm
- Vol. 23 (10) , e2406-e2414
Practice patterns for anticoagulation monitoring after successful typical flutter ablation and related outcomes: An ITHACA-Database study
- 15 April 2026
- Published by Elsevier in Heart Rhythm
- Vol. 23 (10) , e2406-e2414
Practice patterns for anticoagulation monitoring after successful typical flutter ablation and related outcomes: An ITHACA-Database study
- 16 October 2025
- Published by Wiley in Journal of Cardiovascular Electrophysiology
Does a Pacemaker Make a Difference? Long‐Term Outcomes Post‐AF Ablation in Tachy‐Brady Syndrome
Introduction: Tachy‐brady syndrome (TBS), a subtype of sinus node dysfunction, is characterized by alternating bradyarrhythmia and supraventricular tachyarrhythmias. While catheter ablation (CA) for atrial fibrillation (AF) offers improved long‐term outcomes, many patients with TBS undergo permanent pacemaker (PPM) implantation to manage symptomatic bradycardia or enable rate‐control therapy. Data on long‐term outcomes postablation, stratified by PPM status, are limited.Methods: We conducted a retrospective analysis within the multicenter ITHACA registry, which includes patients who underwent AF ablation across five Northwell Health centers from 2015 to 2021. Patients with TBS were stratified by PPM status at index ablation. Primary outcomes were composite failure (AF recurrence with continued antiarrhythmic drug [AAD] use, cardioversion beyond the blanking period, or repeat ablation) beyond the 3‐month blanking period at 12 months and last follow‐up, and all‐cause hospitalization. Secondary outcomes included beta‐blocker and AAD use postablation. Comparisons were performed using Chi‐square tests.Results: Among 3,440 patients who underwent AF ablation, 111 (3.2%) had TBS; 54 (49%) had a PPM at index ablation. Thirty‐four patients were lost to follow‐up. Remaining 77 patients had a median follow‐up of 44.2 months. Of those without a PPM at ablation, 26 (46%) required delayed PPM (median 292 days postablation). At 12 months, composite failure rates were similar between PPM and no‐PPM groups (42% vs. 40%, p = 0.93) and remained comparable at last follow‐up (44% vs. 47%, p = 0.91). Hospitalization was significantly higher in the PPM group compared to no‐PPM (85% vs. 62%, p = 0.01). Subgroup analysis revealed that delayed PPM patients had higher failure at 12 months (65% vs. 42%, p = 0.001) and at last follow‐up (73% vs. 44%, p = 0.056). Furthermore, there was numerically higher readmission between delayed PPM vs no PPM group (69% vs 54%, p = 0.87). More patients in the PPM group remained on beta‐blockers at last follow‐up (61% vs. 35%, p = 0.002), while AAD use declined across groups.Conclusion: In TBS patients undergoing AF ablation, overall failure rates did not differ by initial PPM status, though there was a higher hospital readmission in PPM group, suggesting a potential sicker population. Furthermore, delayed PPM implantation was associated with higher failure and more hospitalizations, suggesting earlier or concurrent PPM may benefit selected patients. Larger prospective studies are needed to define predictors and optimize management.
- 16 October 2025
- Published by Wiley in Journal of Cardiovascular Electrophysiology
Does a Pacemaker Make a Difference? Long‐Term Outcomes Post‐AF Ablation in Tachy‐Brady Syndrome
Introduction: Tachy‐brady syndrome (TBS), a subtype of sinus node dysfunction, is characterized by alternating bradyarrhythmia and supraventricular tachyarrhythmias. While catheter ablation (CA) for atrial fibrillation (AF) offers improved long‐term outcomes, many patients with TBS undergo permanent pacemaker (PPM) implantation to manage symptomatic bradycardia or enable rate‐control therapy. Data on long‐term outcomes postablation, stratified by PPM status, are limited.Methods: We conducted a retrospective analysis within the multicenter ITHACA registry, which includes patients who underwent AF ablation across five Northwell Health centers from 2015 to 2021. Patients with TBS were stratified by PPM status at index ablation. Primary outcomes were composite failure (AF recurrence with continued antiarrhythmic drug [AAD] use, cardioversion beyond the blanking period, or repeat ablation) beyond the 3‐month blanking period at 12 months and last follow‐up, and all‐cause hospitalization. Secondary outcomes included beta‐blocker and AAD use postablation. Comparisons were performed using Chi‐square tests.Results: Among 3,440 patients who underwent AF ablation, 111 (3.2%) had TBS; 54 (49%) had a PPM at index ablation. Thirty‐four patients were lost to follow‐up. Remaining 77 patients had a median follow‐up of 44.2 months. Of those without a PPM at ablation, 26 (46%) required delayed PPM (median 292 days postablation). At 12 months, composite failure rates were similar between PPM and no‐PPM groups (42% vs. 40%, p = 0.93) and remained comparable at last follow‐up (44% vs. 47%, p = 0.91). Hospitalization was significantly higher in the PPM group compared to no‐PPM (85% vs. 62%, p = 0.01). Subgroup analysis revealed that delayed PPM patients had higher failure at 12 months (65% vs. 42%, p = 0.001) and at last follow‐up (73% vs. 44%, p = 0.056). Furthermore, there was numerically higher readmission between delayed PPM vs no PPM group (69% vs 54%, p = 0.87). More patients in the PPM group remained on beta‐blockers at last follow‐up (61% vs. 35%, p = 0.002), while AAD use declined across groups.Conclusion: In TBS patients undergoing AF ablation, overall failure rates did not differ by initial PPM status, though there was a higher hospital readmission in PPM group, suggesting a potential sicker population. Furthermore, delayed PPM implantation was associated with higher failure and more hospitalizations, suggesting earlier or concurrent PPM may benefit selected patients. Larger prospective studies are needed to define predictors and optimize management.
- 7 September 2025
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 36 (11) , 2903-2909
Leveraging Implantable Cardiac Defibrillator Remote Transmissions to Predict the Occurrence of Atrial Fibrillation
Background: Atrial fibrillation (AF) and heart failure (HF) frequently coexist in patients, with the development of AF often preceding HF decompensation. We sought to evaluate whether daily remote monitoring of ICD parameters could predict AF occurrence using machine learning techniques in a real‐world cohort. Methods: Data from patients with primary prevention ICDs transmitted daily to the Northwell centralized remote monitoring center between 2012 and 2021 were extracted. Using this data, an XGBoost model was trained to predict AF occurrence with a 3‐day time horizon using a 14‐day data collection sequence. Model predictive performance was validated retrospectively and prospectively, using mean ROC AUC and PR AUC across all folds. Feature importance was assessed using Shapley additive explanation (SHAP) values. Results: A total of 207 patients, 69.0% male, median age of 65.0 [57, 72] years, median ejection fraction of 30% [25, 40], 13.0% paroxysmal AF, and 35.7% with ischemic cardiomyopathy were monitored for over 36 months. Our model predicted AF occurrence within the following 3 days in 49 (23.7%) patients after a median of 36 months post‐implant with an area under the receiver operating characteristic curve (AUROC) of 0.79 and an area under the precision‐recall curve of 0.10 (AUPRC). The model has a specificity of 99% in the validation data set. Key variables included RV and RA sensing amplitudes as well as the pulse width. Validation was performed using K‐fold cross‐validation methods without a significant drop in performance metrics. Conclusion: This exploratory analysis suggests a machine learning approach has the potential to predict AF from daily remote monitoring of ICD parameters. This risk prediction algorithm requires external validation in a large‐scale multi‐center clinical trial.
- 7 September 2025
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 36 (11) , 2903-2909
Leveraging Implantable Cardiac Defibrillator Remote Transmissions to Predict the Occurrence of Atrial Fibrillation
Background: Atrial fibrillation (AF) and heart failure (HF) frequently coexist in patients, with the development of AF often preceding HF decompensation. We sought to evaluate whether daily remote monitoring of ICD parameters could predict AF occurrence using machine learning techniques in a real‐world cohort. Methods: Data from patients with primary prevention ICDs transmitted daily to the Northwell centralized remote monitoring center between 2012 and 2021 were extracted. Using this data, an XGBoost model was trained to predict AF occurrence with a 3‐day time horizon using a 14‐day data collection sequence. Model predictive performance was validated retrospectively and prospectively, using mean ROC AUC and PR AUC across all folds. Feature importance was assessed using Shapley additive explanation (SHAP) values. Results: A total of 207 patients, 69.0% male, median age of 65.0 [57, 72] years, median ejection fraction of 30% [25, 40], 13.0% paroxysmal AF, and 35.7% with ischemic cardiomyopathy were monitored for over 36 months. Our model predicted AF occurrence within the following 3 days in 49 (23.7%) patients after a median of 36 months post‐implant with an area under the receiver operating characteristic curve (AUROC) of 0.79 and an area under the precision‐recall curve of 0.10 (AUPRC). The model has a specificity of 99% in the validation data set. Key variables included RV and RA sensing amplitudes as well as the pulse width. Validation was performed using K‐fold cross‐validation methods without a significant drop in performance metrics. Conclusion: This exploratory analysis suggests a machine learning approach has the potential to predict AF from daily remote monitoring of ICD parameters. This risk prediction algorithm requires external validation in a large‐scale multi‐center clinical trial.
- Open Access
- 22 August 2025
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 27 (9)
Incidence of laboratory-defined severe intravascular haemolysis across commercially available pulsed field ablation technologies for atrial fibrillation
Aims: Renal failure due to intravascular haemolysis (IH) has been reported after pulsed field ablation (PFA) of atrial fibrillation (AF). However, IH incidence using the accepted laboratory criteria is unknown. Methods and results: In this prospective observational study (Sept 2024–May 2025), consecutive patients undergoing PFA for AF with pentaspline (PS), circular array (CA), or lattice tip (LT) catheters were included. Pre- and post-procedural labs and haemolysis biomarkers were collected. Significant IH was defined as post-procedure free plasma haemoglobin > 100 mg/dL per haematology criteria. Logistic regression (pooled and stratified) was used to identify IH predictors. Among 245 patients (66.9 ± 10.6 years; 68.2% male; 48.2% persistent), PFA was performed using the LT (62), PS (108), or CA (75) catheters. There was a significant difference in the incidence of IH across technologies (37.0%, 26.1%, and 14.7% for PS, CA, and LT, P = 0.002). No demographic or clinical parameters were associated with higher IH risk, while the use of PS was the only independent predictor [odds ratio (OR) 3.42, P = 0.001] of IH. The number of PF lesions increased risk for IH only within the PS group (OR 1.03, P = 0.049). Routine post-ablation laboratories had poor sensitivity/specificity to define severe IH. Conclusion: Although over 17% of the cohort met the haematologic definition for significant IH, the absence of clinically significant renal impairment suggests that this threshold may not accurately reflect clinically meaningful haemolysis following PFA. The absence of clinical predictors or laboratory surrogates suggests that the rare risk of renal injury must be balanced with the well-established benefits of PFA when lesions are delivered in moderation optimizing tissue contact.
- 22 August 2025
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 27 (9)
Open AccessIncidence of laboratory-defined severe intravascular haemolysis across commercially available pulsed field ablation technologies for atrial fibrillation
Aims: Renal failure due to intravascular haemolysis (IH) has been reported after pulsed field ablation (PFA) of atrial fibrillation (AF). However, IH incidence using the accepted laboratory criteria is unknown. Methods and results: In this prospective observational study (Sept 2024–May 2025), consecutive patients undergoing PFA for AF with pentaspline (PS), circular array (CA), or lattice tip (LT) catheters were included. Pre- and post-procedural labs and haemolysis biomarkers were collected. Significant IH was defined as post-procedure free plasma haemoglobin > 100 mg/dL per haematology criteria. Logistic regression (pooled and stratified) was used to identify IH predictors. Among 245 patients (66.9 ± 10.6 years; 68.2% male; 48.2% persistent), PFA was performed using the LT (62), PS (108), or CA (75) catheters. There was a significant difference in the incidence of IH across technologies (37.0%, 26.1%, and 14.7% for PS, CA, and LT, P = 0.002). No demographic or clinical parameters were associated with higher IH risk, while the use of PS was the only independent predictor [odds ratio (OR) 3.42, P = 0.001] of IH. The number of PF lesions increased risk for IH only within the PS group (OR 1.03, P = 0.049). Routine post-ablation laboratories had poor sensitivity/specificity to define severe IH. Conclusion: Although over 17% of the cohort met the haematologic definition for significant IH, the absence of clinically significant renal impairment suggests that this threshold may not accurately reflect clinically meaningful haemolysis following PFA. The absence of clinical predictors or laboratory surrogates suggests that the rare risk of renal injury must be balanced with the well-established benefits of PFA when lesions are delivered in moderation optimizing tissue contact.
- 16 July 2025
- Published by Elsevier in Heart Rhythm
- Vol. 23 (2) , e217-e219
Differences in intravascular hemolysis between 2 technologies for pulse field ablation of atrial fibrillation
- 16 July 2025
- Published by Elsevier in Heart Rhythm
- Vol. 23 (2) , e217-e219
Differences in intravascular hemolysis between 2 technologies for pulse field ablation of atrial fibrillation
- 29 November 2024
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 36 (2) , 314-322
Hospital and Post‐Discharge Mortality in Patients With Acute Coronary Syndrome and Ventricular Ectopy
Introduction: Ventricular premature depolarizations (VPDs) in the setting of acute coronary syndrome (ACS) were associated with increased hospital mortality in the early revascularization era.Objective: Examine the predictive value of VPDs and their morphology for hospital and post‐discharge mortality in patients admitted for ACS.Methods: We identified patients admitted with ACS across 13 Northwell Health Hospitals from 2015 to 2021 and had VPDs captured on a 12‐lead ECG or full disclose telemetry. We characterized and reported descriptively the VPDs based on bundle branch block pattern (right or RBBB vs. left or LBBB), frontal (inferior vs. superior) and horizontal (leftward vs. rightward) axis, QRS width, and coupling interval (CI). Hierarchical generalized linear mixed modeling was used to assess the association between VPDs and hospital mortality, while Cox regression was used for post‐discharge mortality.Results: Of 18 009 patients admitted for ACS, we identified 627 patients with VPDs with complete data (65.7% RBB, 49.9% superior, and 63.4% leftward axis). Mean VPD QRS width and CI were 175 ± 30 and 523 ± 157 ms, respectively. Hospital mortality was higher in the VPD group (7.8% vs. 4.9%, p < 0.001) with most common mode of death being arrhythmic (28.1% vs. 14.5%). After adjusting for clinical covariates, only VPDs with RBBB patterns were associated with hospital mortality (OR 2.26, 95% CI 1.06−4.82). Conversely, age‐adjusted post‐discharge mortality was higher only for patients with superior axis VPDs (HR 1.59, 95% CI 1.13−2.24).Conclusion: Among patients with VPDs during an ACS admission, presence of RBBB pattern predicts hospital mortality, whereas superior axis is associated with post‐discharge mortality.
- 29 November 2024
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 36 (2) , 314-322
Hospital and Post‐Discharge Mortality in Patients With Acute Coronary Syndrome and Ventricular Ectopy
Introduction: Ventricular premature depolarizations (VPDs) in the setting of acute coronary syndrome (ACS) were associated with increased hospital mortality in the early revascularization era.Objective: Examine the predictive value of VPDs and their morphology for hospital and post‐discharge mortality in patients admitted for ACS.Methods: We identified patients admitted with ACS across 13 Northwell Health Hospitals from 2015 to 2021 and had VPDs captured on a 12‐lead ECG or full disclose telemetry. We characterized and reported descriptively the VPDs based on bundle branch block pattern (right or RBBB vs. left or LBBB), frontal (inferior vs. superior) and horizontal (leftward vs. rightward) axis, QRS width, and coupling interval (CI). Hierarchical generalized linear mixed modeling was used to assess the association between VPDs and hospital mortality, while Cox regression was used for post‐discharge mortality.Results: Of 18 009 patients admitted for ACS, we identified 627 patients with VPDs with complete data (65.7% RBB, 49.9% superior, and 63.4% leftward axis). Mean VPD QRS width and CI were 175 ± 30 and 523 ± 157 ms, respectively. Hospital mortality was higher in the VPD group (7.8% vs. 4.9%, p < 0.001) with most common mode of death being arrhythmic (28.1% vs. 14.5%). After adjusting for clinical covariates, only VPDs with RBBB patterns were associated with hospital mortality (OR 2.26, 95% CI 1.06−4.82). Conversely, age‐adjusted post‐discharge mortality was higher only for patients with superior axis VPDs (HR 1.59, 95% CI 1.13−2.24).Conclusion: Among patients with VPDs during an ACS admission, presence of RBBB pattern predicts hospital mortality, whereas superior axis is associated with post‐discharge mortality.
- 24 October 2024
- Published by Elsevier in Heart Rhythm
- Vol. 22 (7) , e74-e84
Methods and techniques to optimize energy delivery using the circular array pulsed field ablation catheter
- 24 October 2024
- Published by Elsevier in Heart Rhythm
- Vol. 22 (7) , e74-e84
Methods and techniques to optimize energy delivery using the circular array pulsed field ablation catheter